AI assistant
ACRUX LIMITED — Capital/Financing Update 2013
Jul 24, 2013
64293_rns_2013-07-24_10de844c-dd21-47f6-8ddc-9524b1c21db0.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
25 JULY 2013
ACRUX (ACR) - ASX ANNOUNCEMENT
AXIRON NET SALES, QUARTER TO 30 JUNE 2013
Acrux (ASX: ACR) today confirmed that Eli Lilly reported Axiron net sales of US$47 million in its financial results for the quarter ended 30 June 2013, up from US$37 million for the previous quarter to 31 March 2013.
Axiron net sales for Acrux’s financial year ended 30 June 2013 are shown in the following table:
| llowing table: | llowing table: | |||||||
|---|---|---|---|---|---|---|---|---|
| Q3 2012 | Q4 2012 | Q1 2013 | Q2 | 013 | Total FY 2013 | |||
| US$16m | US$24m | US$37m | US$ | 7m | US$124m |
For the year ended 30 June 2013, Acrux earned royalties from Axiron of $14 million, up from $6 million in the previous year.
Acrux expects the average royalty percentage of net sales to increase in the year ending 30 June 2014. In addition to royalties, Acrux will receive a milestone payment of US$25 million in March 2014 if the worldwide net sales of Axiron in the 2013 calendar year exceed US$100 million. Net sales in the first half of the calendar year were US$84 million.
Contact
Jon Pilcher, CFO: 0438 422 271
About Acrux
-
Acrux is an Australian drug delivery company, developing and commercialising a range of patient-preferred, patented pharmaceutical products for global markets, using its innovative liquid technology to administer drugs through the skin.
-
Acrux has products marketed by licensees in the United States, Europe, Canada and Australia and in registration or development.
==> picture [123 x 66] intentionally omitted <==
==> picture [360 x 66] intentionally omitted <==
==> picture [106 x 66] intentionally omitted <==